1. Chiò, A. et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 10, 310–323. https://doi.org/10.3109/17482
960802566824 (2009).
2. Ludolph, A. C. et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 2020(87), 206–216.
https://doi.org/10.1002/ana.25661[publishedOnlineFirst:19December (2019).
3. Khamankar, N. et al. Associative increases in amyotrophic lateral sclerosis Survival duration with non-invasive ventilation initiation and usage protocols. Front Neurol 9, 578. https://doi.org/10.3389/fneur.2018.00578 (2018).
4. Bouteloup, C. et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 2009(256), 1236–1242.
https://doi.org/10.1007/s00415-009-5100-z[publishedOnlineFirst:24March (2009).
5. Steyn, F. J. et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg
Psychiatry 2018(89), 1016–1023. https://doi.org/10.1136/jnnp-2017-317887[publishedOnlineFirst:1May (2018).
6. He, J. et al. Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis. J Neurol https://doi.org/10.1007/
s00415-021-10716-1 (2021).
7. Steyn, F. J. et al. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Commun 2, fcaa154. https://
doi.org/10.1093/braincomms/fcaa154(2020) (2020).
8. Nakamura, R. et al. Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic
lateral sclerosis. Sci Rep 11, 17943. https://doi.org/10.1038/s41598-021-97196-5 (2021).
9. Marin, B. et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients.
J Neurol Neurosurg Psychiatry 2011(82), 628–634. https://doi.org/10.1136/jnnp.2010.211474[publishedOnlineFirst:19November
(2010).
10. Dorst, J. et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral
sclerosis. J Neurol 2011(258), 613–617. https://doi.org/10.1007/s00415-010-5805-z (2010).
11. Huang, R. et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a metaanalysis. Amyotroph Lateral Scler Frontotemporal Degener 2015(16), 359–365. https://doi.org/10.3109/21678421.2015.1047454
(2015).
12. Mandrioli, J. et al. Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci 2017(38), 2177–2182.
https://doi.org/10.1007/s10072-017-3138-8 (2017).
13. Rafiq, M. K. et al. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime
clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 2015(16), 478–484. https://doi.org/10.3109/21678421.2015.10625
17[publishedOnlineFirst:10July (2015).
14. Ikeda, K. et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients
with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 2012(51), 1501–1508. https://doi.org/10.2169/internalme
dicine.51.7465[publishedOnlineFirst:15June (2012).
Scientific Reports |
Vol:.(1234567890)
(2022) 12:1826 |
https://doi.org/10.1038/s41598-022-05714-w
www.nature.com/scientificreports/
15. Wuolikainen, A. et al. Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis
that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS ONE 9, e113619. https://doi.org/10.1371/journal.pone.0113619
(2014).
16. Chiò, A. et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73, 1681–1685.
https://doi.org/10.1212/WNL.0b013e3181c1df1e (2009).
17. Chiò, A. et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.
JAMA Neurol 71, 1134–1142. https://doi.org/10.1001/jamaneurol.2014.1129 (2014).
18. Barros, A. N. A. B. et al. Association of copper status with lipid profile and functional status in patients with amyotrophic lateral
sclerosis. J Nutr Metab 2018, 5678698. https://doi.org/10.1155/2018/5678698 (2018).
19. Liu, J. et al. Lipid profile in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Neurol 11,
567753. https://doi.org/10.3389/fneur.2020.567753 (2020).
20. Ingre, C. et al. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology 2020(94), e1835–e1844. https://
doi.org/10.1212/WNL.0000000000009322 (2020).
21. Brooks, B. R. et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler
Other Motor Neuron Disord 1, 293–299. https://doi.org/10.1080/146608200300079536 (2000).
22. Cedarbaum, J. M. et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function.
BDNF ALS Study Group (Phase III). J Neurol Sci 169, 13–21. https://doi.org/10.1016/s0022-510x(99)00210-5 (1999).
23. Nordestgaard, B. G. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications
including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society
and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016(37), 1944–1958. https://doi.org/10.
1093/eurheartj/ehw152[publishedOnlineFirst:26April (2016).
24. Takaoka, A. et al. Comparison of energy metabolism and nutritional status of hospitalized patients with Crohn’s disease and those
with ulcerative colitis. J Clin Biochem Nutr 2015(56), 208–214. https://doi.org/10.3164/jcbn.14-95[publishedOnlineFirst:14April
(2015).
25. Desport, J. C. et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 74,
328–334. https://doi.org/10.1093/ajcn/74.3.328 (2001).
26. Harris, J. A. & Benedict, F. G. A biometric study of human basal metabolism. Proc Natl Acad Sci USA 4, 370–373. https://doi.org/
10.1073/pnas.4.12.370 (1918).
27. Miyake, R. et al. Validity of predictive equations for basal metabolic rate in Japanese adults. J Nutr Sci Vitaminol (Tokyo) 57,
224–232. https://doi.org/10.3177/jnsv.57.224 (2011).
28. Kanda, Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013(48),
452–458. https://doi.org/10.1038/bmt.2012.244 (2012).
29. Dedic, S. I. et al. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis?. Neurol Res
2012(34), 576–580. https://doi.org/10.1179/1743132812Y.0000000049 (2012).
30. Andersson, S. et al. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl
Acad Sci USA 2005(102), 3857–3862. https://doi.org/10.1073/pnas.0500634102 (2005).
31. Choi, C. I. et al. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J Neurol Sci 2008(268),
40–47. https://doi.org/10.1016/j.jns.2007.10.024 (2007).
32. Tang, S. et al. Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci Rep
9, 1350. https://doi.org/10.1038/s41598-018-38014-3 (2019).
33. Lehti, M. et al. High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation
2013(128), 2364–2371. https://doi.org/10.1161/CIRCULATIONAHA.113.001551 (2013).
34. Wang, S. & Peng, D. Regulation of adipocyte autophagy–the potential anti-obesity mechanism of high density lipoprotein and
apolipoproteinA-I. Lipids Health Dis 11, 131. https://doi.org/10.1186/1476-511X-11-131 (2012).
35. Manzo, E. et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife https://doi.org/10.7554/
eLife.45114 (2019).
36. Ferri, A. & Coccurello, R. What is “hyper” in the ALS hypermetabolism?. Mediators Inflamm 2017, 7821672. https://doi.org/10.
1155/2017/7821672 (2017).
37. Bruckert, E. et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med
Res Opin 21, 1927–1934. https://doi.org/10.1185/030079905X74871 (2005).
Acknowledgements
We appreciate the support of Jun Matsubayashi and Shoji Momokawa from the Center for Clinical Research
and Advanced Medicine at the Shiga University of Medical Science. We thank all the patients with ALS who
participated in this study.
Author contributions
R.N. and M.U. designed the research, analyzed the data, and wrote the manuscript. M. S., A. K., I. Y., and N. O.
analyzed the data. M.K. and M.S. measured the RQ and REE and analyzed the data. All authors reviewed the
manuscript.
Funding
This study was supported by an intramural research fund from the Shiga University of Medical Science.
Competing interests The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-022-05714-w.
Correspondence and requests for materials should be addressed to M.U.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Scientific Reports |
(2022) 12:1826 |
https://doi.org/10.1038/s41598-022-05714-w
Vol.:(0123456789)
www.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2022
Scientific Reports |
Vol:.(1234567890)
(2022) 12:1826 |
https://doi.org/10.1038/s41598-022-05714-w
10
...
論文の公開元へ
